Real-World Efficacy of Second-Line Toripalimab in Patients With Advanced NoneSmall-Cell Lung Cancer.
Clarify the real-world efficacy and safety of second line Toripalimab advanced nonesmall-cell lung cancer in a retrospective multi center trial.
Non adenocarcinoma and a large number of metastatic sites correlated with poor progression-free sur vival (PFS). PFS and overall survival (OS) were longer in patients with pembrolizumab-related adverse events;however, PFS and OS were shorter in patients with interstitial lung disease